Compare Broadcom Inc (AVGO) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Broadcom Inc vs BridgeBio Pharma Inc — how do they compare? Broadcom Inc trades at $418.23 (market cap $2.01T), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: Broadcom Inc is far larger — about 121× BridgeBio Pharma Inc's market cap, and Broadcom Inc pays a 0.62% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| AVGO | BBIO | |
|---|---|---|
Market Cap | $2.01T | $16.61B |
Sector | Technology | Health |
52-Week High | $481.57 | $90.17 |
52-Week Low | $289.60 | $47.29 |
Enterprise Value | $2.05T | $18.16B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Broadcom (AVGO) trades at $427.76, up 1.71% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported robust earnings beats, with Q1 2026 EPS of $2.44 exceeding expectations, and AI semiconductor revenue surged 143% year-over-year to $10.8 billion in Q2 2026. Valuation ratios are elevated, with a P/E of 71.17, reflecting high growth expectations.
Outlook remains positive driven by AI demand, with CEO Hock Tan forecasting over $100 billion in AI semiconductor revenue by 2027. Risks include competitive pressures and high debt levels. Analysts are overwhelmingly bullish, with a consensus price target of $510.21, implying 19% upside from current levels.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
